When tumor size reached approximately 50 mm3, mice were randomly assigned to five groups and treated by oral gavage with the NOX1-specific inhibitor GKT771, the broad-spectrum inhibitor GKT831, or the anti–VEGFR-2 blocking antibody DC101. Here, NOX1 is linked to neoplasm.